You are here

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Last updated on November 9, 2018

FOR MORE INFORMATION
Study Location
Profil Institute for Clinical Research, Inc.
Chula Vista, California, 91911 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Men and women of non-childbearing potential with Type 2 Diabetes Mellitus

- Subjects on stable doses of metformin >/= 1500 mg daily (SAD cohorts) or >/= 1000 mg
daily (MAD cohorts) x 30 days prior to screening

- HbA1c 7-10% (SAD Cohorts) or 6.5-10% (MAD cohorts) inclusive at screening

- Fasting C-peptide >1.12 ng/mL (SAD cohorts) or >/= 0.8 mg/mL (MAD cohorts) at
screening

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of Type 1 diabetes mellitus

- Evidence of diabetic complications with significant end-organ damage

- History of chronic pancreatitis or at high risk for pancreatitis

- Poorly controlled hypertension

- History of cardiovascular or cerebrovascular event or procedure

NCT02211261
Pfizer
Completed
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus
A first in human study to determine the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus
Not Provided
Interventional
Phase 1
Allocation: Randomized
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Type 2 Diabetes Mellitus
  • Biological: PF-06293620
    subcutaneous, single dose 0.3 mg/kg
  • Biological: Placebo
    Subcutaneous normal saline single dose
  • Biological: PF-06293620
    Subcutaneous, single dose 1.0 mg/kg
  • Biological: PF-06293620
    Subcutaneous single dose 3 mg/kg
  • Biological: PF-06293620
    Subcutaneous single dose 6 mg/kg
  • Biological: PF-06293620
    Intravenous infusion single dose 1 mg/kg
  • Biological: Placebo
    Intravenous infusion normal saline single dose
  • Biological: PF-06293620
    Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
  • Biological: Placebo
    Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
  • Biological: PF-06293620
    Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
  • Biological: PF-06293620
    Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
  • Biological: PF-06293620
    Subcutaneous injection multiple dose TBD mg (Days TBD)
  • Biological: Placebo
    Subcutaneous injection normal saline multiple dose (Days TBD)
  • Experimental: Cohort 1-PF-06293620 or placebo
    Single Ascending Dose PF-06293620 or placebo
    Interventions:
    • Biological: PF-06293620
    • Biological: Placebo
  • Experimental: Cohort 2-PF-06293620 or placebo
    Single Ascending Dose PF-06293620 or placebo
    Interventions:
    • Biological: PF-06293620
    • Biological: Placebo
  • Experimental: Cohort 3-PF-06293620 or placebo
    Single Ascending Dose PF-06293620 or placebo
    Interventions:
    • Biological: PF-06293620
    • Biological: Placebo
  • Experimental: Cohort 4-PF-06293620 or placebo
    Single Ascending Dose PF-06293620 or placebo
    Interventions:
    • Biological: PF-06293620
    • Biological: Placebo
  • Experimental: Cohort 5-PF-06293620 or placebo
    Single Ascending Dose PF-06293620 or placebo
    Interventions:
    • Biological: PF-06293620
    • Biological: Placebo
  • Experimental: Cohort 6-PF-06293620 or placebo
    Multiple Ascending Dose PF-06293620 or placebo
    Interventions:
    • Biological: PF-06293620
    • Biological: Placebo
  • Experimental: Cohort 7 PF-06293620 or placebo
    Multiple Ascending Dose PF-06293620 or placebo
    Interventions:
    • Biological: PF-06293620
    • Biological: Placebo
  • Experimental: Cohort 8-PF-06293620 or placebo
    Multiple Ascending Dose PF-06293620 or placebo
    Interventions:
    • Biological: PF-06293620
    • Biological: Placebo
  • Experimental: Cohort 9-PF-06293620 or placebo
    Multiple Ascending Dose PF-06293620 or placebo
    Interventions:
    • Biological: PF-06293620
    • Biological: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
84
January 2017
January 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women of non-childbearing potential with Type 2 Diabetes Mellitus
  • Subjects on stable doses of metformin >/= 1500 mg daily (SAD cohorts) or >/= 1000 mg daily (MAD cohorts) x 30 days prior to screening
  • HbA1c 7-10% (SAD Cohorts) or 6.5-10% (MAD cohorts) inclusive at screening
  • Fasting C-peptide >1.12 ng/mL (SAD cohorts) or >/= 0.8 mg/mL (MAD cohorts) at screening

Exclusion Criteria:

  • History of Type 1 diabetes mellitus
  • Evidence of diabetic complications with significant end-organ damage
  • History of chronic pancreatitis or at high risk for pancreatitis
  • Poorly controlled hypertension
  • History of cardiovascular or cerebrovascular event or procedure
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02211261
B3501001
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now